Purpose of review The debate on the merits of observational studies as compared with randomized trials is ongoing. We will briefly touch on this subject, and demonstrate the role of cohort studies for the description of infectious disease patterns after transplantation. The potential benefits of cohort studies for the clinical management of patients outside of the expected gain in epidemiological knowledge are reviewed. The newly established Swiss Transplantation Cohort Study and in particular the part focusing on infectious diseases will serve as an illustration.
INTRODUCTION
Knowledge of the epidemiology of infectious diseases complications after solid organ transplantation is of major importance for both the individual care of the transplant recipient and the implementation of prevention strategies. The temporal pattern of infections after transplantation directs the diagnostic approach and empiric therapy in a transplant recipient with a suspected infection. From the early observations of dedicated specialists and observational studies, a timeline with three distinct episodes of infectious diseases after transplantation was distinguished: an early postoperative phase lasting up to 1 month which is characterized by typical postoperative complications is followed by a period of most intense immunosuppression, which is associated with opportunistic infections. After 6 months, stabilization of graft function usually allows to taper immunosuppression to a lower level. The risk of an infectious disease complication decreases, without ever approaching the one of an immunocompetent individual [1] .
The concept of the timeline of posttransplant infections has evolved over time. On an epidemiological level, the advent of new immunosuppressive agents and the demographic changes in the donor and recipient population has greatly increased the variables influencing the risk of infections. The donor as a source of infection is increasingly recognized [2] . Preventive strategies have had a profound impact on the temporal pattern of certain infections. Although the initial phase from 1980s onwards was characterized by a relatively small number of immunosuppressive drugs and regimens and limited antiviral as well as antifungal compounds, the recent years have witnessed an increase of both immunosuppressive and antimicrobial strategies [3] . As a consequence, the timeline is changing more rapidly, with more variables influencing the risk of infection after transplantation [1] . Given the increased diversity of immunosuppressive regimens and the advent of biological agents with an often very profound and prolonged effect on the immunity of recipients, local surveillance of infectious diseases events has become even more important.
Comprehensive data on infectious diseases are rare, despite their important contribution to morbidity and mortality after transplantation. Our knowledge of the epidemiology of infectious diseases after transplantation is mainly derived from retrospective case series, or the analysis of 'safety endpoints' in large randomized trials on immunosuppressive agents. Unfortunately, these endpoints were not collected comprehensively, and often without stringent definitions. The lack of uniform reporting prompted the American Society of Transplantation Infectious Diseases Working Group on Infectious Diseases Monitoring to publish recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials [4 & ]. This initiative has greatly improved collection of infectious diseases events, and has had a unifying influence on definitions beyond randomized trials. A similar effort resulted in recently published uniform definitions to describe donorderived diseases [5] . The very stringent selection of patients included in randomized trials, however, is an important obstacle that diminishes the generalizability of findings. Follow-up is mostly restricted by the duration of the study.
Registries would be ideally suited to provide a broader view on infectious diseases events. Unfortunately, the focus of registries is not on infectious disease. One of the largest is the US-based Scientific Registry of Transplant Recipients (http:// www.srtr.org/). Many crucial variables including type of immunosuppression, graft and patient survival, diagnoses leading to transplantation are collected. Serologies for human immunodeficiency virus, cytomegalovirus, Epstein-Barr virus and hepatitis B and C are collected, and information on antiviral therapy and treatment of BK-virus is requested. Infection can be indicated as a contributory reason for graft failure. Specific information on infectious disease events is not collected. Although the importance of this information has been documented by a number of associative studies, such as studying a link between hepatitis C seropositivity and survival or incidence of posttransplantation lymphoproliferative disorder [6,7 & ], information on infectious diseases is very limited. The European Liver Transplant Registry (http://www.eltr.org/) focuses on outcome but does not collect any infectious disease data. It is without any doubt that these and other registries have had a pivotal role in transplant epidemiology, but their contribution to knowledge on infectious disease is limited.
A notable exception is the Spanish Network for Research on Infection in Transplantation (RESITRA) (http://www.reipi.org/). This network has collected an impressive amount on data resulting in a number of important publications. A broad range of topics from bloodstream infections, incidence of tuberculosis to donor-derived infections has been covered [8-10,11 & ,12,13] . This landmark cohort study has demonstrated that a carefully designed observational study can play a pivotal role in the advancement of infectious disease knowledge. Systematic collection, however, is no longer performed.
KEY POINTS
The influence of prophylactic strategies and new immunosuppressive strategies on the temporal pattern of infectious diseases after solid organ transplantation is difficult to assess, as comprehensive data on posttransplant infections are limited.
Well designed prospective observational studies are particularly qualified to improve knowledge of infectious diseases patterns after transplantation and allow taking appropriate measures if required.
The benefits of large cohort studies go beyond the scientific gain and include an improvement in clinical care through benchmarking and intensified collaboration.
The US-based Transplant-Associated Infection Surveillance Network (TRANSNET) collected data from 23 US transplant centers including hematopoetic stem cell patients and solid organ recipients with a focus on invasive fungal infections. The study was primarily designed to assess the burden of invasive fungal infection; no formal risk analysis was possible due to limited additional data [14, 15] .
THE UNIQUE FEATURES OF THE SWISS TRANSPLANT COHORT STUDY
Data reflecting the clinical reality are needed to make informed choices and detect emerging infections early. To overcome some of these obstacles, the Swiss Transplant Cohort Study (STCS) (www.stcs.ch) was created. The STCS is a prospective multicenter study enrolling all solid organ transplant (SOT) recipients in Switzerland. The modular system allows collecting organ-specific transplantation data, as well as important general data regardless of the type of organ transplanted. Infectious disease episodes are collected based on internationally used definitions as distinct events. ( [16 & ], submitted). The STCS has been modeled on the Swiss HIV cohort study, which has been a very successful tool for epidemiological research for many years and serves as example [17] .
The STCS is designed as a dynamic, open cohort, with the goal of an extensive follow-up. A minimal data set of data is required by law for all patients transplanted in Switzerland, and an informed consent is obtained for the larger dataset. As of August 2012, with a consent rate of more than 95%, 2428 patients were included. The STCS has some unique features, which distinguish this cohort study from established registries. It is, to our knowledge, the only nationwide cohort aiming at including all transplant recipients. Data collection is systematic, prospective and based on predefined definitions, on all aspects of transplantation (outcome, rejection, malignancy, psychosocial, and infectious disease data, laboratory data) at the time of transplantation, after 6 months and yearly thereafter. Besides general data, each organ has its own set of transplantspecific data agreed upon. Data collection is performed by study nurses in close collaboration with the transplant specialists. In case of the infectious disease data, the local transplant infectious diseases specialists are reviewing the laboratory and the clinical results prior to data entry. Regular meetings ensure uniform interpretation of the definitions for collection and allow adapting the definitions if problems arise. The variables collected and audited on regular basis for assessment of infectious diseases events in the STCS are as follows: The ongoing yearly collection will accumulate long-term follow-up data, which is indispensable to answer many open questions. The design will allow comparing outcomes within the cohort, such as between centers or specific organ transplant programs. No control population is planned so far. By virtue of the large number of patients enrolled, this design will provide a statistical power sufficient to address many research questions. Furthermore, collaboration with other transplant cohort may still increase this power. In addition, in the future comparison studies with the normal population may be of interest at some point.
NONSCIENTIFIC BENEFITS
Regular analysis of different outcome variables may raise questions with respect to quality control and enables to recognize trends early. Uncommon patterns observed at one center can be compared with the nationwide data, and enable an informed response if deemed necessary. Infectious diseases data are rarely collected systematically outside of trials or of specific research questions. Incidence rates of any kind of infectious diseases events can be compared between centers or analyzed as a whole.
During the course of designing and implementing the entire cohort, a transplant infectious diseases group representing all transplant centers was formed. The intense and regular contact necessary has been instrumental in fostering a close collaboration beyond scientific projects. Writing of the STCS infectious diseases event definitions guarantees a uniform and consistent reporting in all centers, allowing to effectively comparing data. National guidelines on vaccination of solid organ recipients will be published shortly. Challenging cases on both the donor and recipient side are discussed regularly in real-time, supporting clinical decision making. By the same token, donor-derived infections are communicated early for clinical follow-up in other recipients and the delivery of interventions. Inconsistencies of infectious diseases events reported revealed in the course of data analysis for ongoing studies have forced all centers to review difficult cases. The benefit of all this nonscientific fallout is difficult to measure, but awareness of hitherto under-recognized questions has increased. A regular feedback on relevant outcome data to all programs and centers will become a key asset for patients, physicians and programs.
OBSERVATIONAL STUDIES
The merits of observational studies for patientoriented research are intensely debated. The controversy stems from older evidence that results of nonrandomized trials or historical controls are only of limited value when compared with randomized trials and tend to overestimate treatment effects [18] . Recent studies, however, have documented the equivalence of both designs for evaluation of treatment outcome. An unconditional requirement is an optimal quality of observational studies in the form of a cohort or case-control design, as well as a very high enrolment rate to minimize selection bias [19,20 && ] compared the effectiveness of antiretroviral therapy in observational studies as compared with randomized trials. Not all observational studies may perform alike, and a careful interpretation is warranted. Randomized trials have their limitations as well. Generalizability is limited by the restricted access favoring only optimal patients. Disease severity and comorbidity is often broader than reflected in the trial population [19] .
CONCLUSION
For the description of relevant events and outcomes, the optimal design consists of well done prospective observational cohort studies with predefined endpoints and an all-inclusive approach. Recent research has demonstrated the usefulness of such studies for treatment effects as well. Clearly, as with randomized trials, the limitation of the respective design has to be taken into account. An underestimated benefit of the creation of a long-term cohort studies lies in an intensified collaboration between centers and across transplant programs. Although difficult to measure, it is likely that this will result in an improvement of clinical care.
